Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
Noosa News23 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
Noosa News12 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News22 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
Noosa News21 hours agoMissing man, Maroochydore – Queensland Police News